← Back to patent-cliff list
非诺贝特
Tier C — Watch / tradeFenofibrate
艾伯维
Originator
1985
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：PPAR
Brand：<span class="highlightText">Fenofibrate</span> IDD-P、Lipantil、Antara、Lipoclar、Fenoglide、Pharmavit、Lipirex、Triglide、Lipidil、Fulcro、Tricor、Lipofen、Lipanthyl、Secalip、Fenobrate、Fenogal
Indications (approved)：高胆固醇血症、高甘油三酯血症
Regional status
US
临床三期
2021-03-05
EU
临床二期
2022-04-07
China
批准上市
1985-01-01
Japan
临床二期
2020-12-23
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fenofibrate?
Approved indications include: 高胆固醇血症, 高甘油三酯血症.
When does the Fenofibrate patent expire?
No public expiry year is available for Fenofibrate yet; this page updates once verified.
How do I get a quote for Fenofibrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25